On Monday, Shares of Macy’s, Inc. (NYSE:M), gained 3.78% to $40.06.
Macy’s, customers will get a sneak preview of what happens behind the scenes in preparation for one of the biggest shopping events of the season in the retailer’s new Black Friday commercial. The TV spot’s star-filled storyline features Ariana Grande, Clinton Kelly, Heidi Klum, Ryan Seacrest, Jessica Simpson, Thalia Sodi and Martha Stewart assisting prep for the big weekend. Previewing recently on youtube.com/macys and planned to break on television on Sunday, Nov. 22, the commercial reminds customers to shop Macy’s starting at 6 p.m. on Thanksgiving for the best deals, plus a chance to instantly win $1 million in Macy’s gift codes and branded prizes.
“Who better than an ensemble of Macy’s stars to bring a new level of fun and excitement to this year’s Black Friday commercial,” said Martine Reardon, Macy’s chief marketing officer. “From Clinton Kelly assisting an elf dress her best and Jessica Simpson slashing prices to Thalia Sodi leading a dance in her department and Ryan Seacrest hosting it all, fans will see their favorite celebrities getting Macy’s ready to offer the best deals on the most desirable gifts this holiday season. Only Macy’s can give America a Parade on Thanksgiving and the biggest sale of the year on Black Friday.”
Reinforcing why America’s Department Store is the best place to shop on Black Friday weekend, Macy’s Black Friday Ensemble features Macy’s stars as they spend Wednesday night prepping the store for one of the biggest sales of the season.
Macy’s, Inc., together with its auxiliaries, operates stores and Internet Websites in the United States. Its stores and Websites sell a range of merchandise, counting apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods.
Shares of Intuit Inc. (NASDAQ:INTU), declined -2.10% to $101.03, during its last trading session.
Intuit Inc., declared the addition of new security features in TurboTax, reflecting the continued role it is playing in support of industry and government’s collaborative efforts to fight fraud and protect taxpayer information.
The declarement is part of a joint consumer education and awareness campaign being launched by the Internal Revenue Service, state revenue agencies and the tax preparation industry to assist consumers understand how they can protect their identities online and reduce the risk of becoming victims of tax fraud.
The cooperative effort between government and industry has resulted in new ways to further authenticate taxpayers’ identities. Additional requirements for information sharing and reporting will further strengthen the tax system and give taxpayers greater confidence when they file returns.
Intuit Inc. provides business and financial administration solutions for small businesses, consumers, and accounting professionals primarily in the United States, Canada, the United Kingdom, Australia, India, and Singapore.
Finally, Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT), ended its last trade with 6.24% gain, and closed at $30.81.
PTC Therapeutics, declared that it has accomplished enrollment of ACT CF, the company’s second Phase 3 clinical trial of Translarna (ataluren) for patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations in cystic fibrosis are categorized as Class I mutations, which are the most difficult to treat, as they result in little or no production of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. About 10 percent of cystic fibrosis patients have their disease as a result of a nonsense mutation.
“We are very happy by the enthusiastic response from our clinical investigators and strong interest from patients to take part in our ACT CF study,” said Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. “Based on the results from our previous Phase 3 study, we believe that Translarna has the potential to meaningfully improve lung function and decrease pulmonary exacerbations in nonsense mutation cystic fibrosis patients by targeting the underlying cause of the disease.”
On September 30, 2015, the European Medicines Agency (EMA) validated the submission of a variation for a new indication for Translarna for the treatment of nmCF. The company’s regulatory application for Translarna in nmCF was based on clinical data and analyses generated from the company’s formerly accomplished Phase 3 double-blind, placebo-controlled study comparing Translarna to placebo in nmCF patients. Translarna received marketing authorization in Europe in August 2014 for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes.
You may also like
Major Losers Overview: UniPixel (NASDAQ:UNXL), XBi...
Investors Focused Stocks: Amazon.com, Inc (NASDAQ:...
Stocks News Alert: Terra Form Power Inc (NASDAQ:TE...
Stocks Under Consideration: AT&T Inc. (NYSE:T...
Hot Movers to Watch: Sprint Corp (NYSE:S), Medtron...
Hot Movements: Rite Aid Corporation (NYSE:RAD), No...
Active Movers of Yesterday: Yahoo! Inc. (NASDAQ:YH...
Active Stocks to Watch For: Williams Companies Inc...
Active Stocks in Focus: Groupon Inc (NASDAQ:GRPN),...